1. Abott T, John AV. The cost of US pharmaceutical price reductions: a financial simulation model of R&D decisions. Working paper. Cambridge: National Bureau of Economic Research. 2005.
http://www.nber.org/papers/w11114.pdf
. Accessed 8 June 2014.
2. Anello E. A framework for good governance in the public pharmaceutical sector. 2008.
3. Bond E, Saggi K. Compulsory licensing, price controls, and access to patented foreign products. 2012.
http://www.wipo.int/edocs/mdocs/mdocs/en/wipo_ip_econ_ge_4_12/wipo_ip_econ_ge_4_12_ref_saggi.pdf
. Accessed 10 May 2014.
4. Burgess CL, Kand E. “The Next Hot Thing”? DOJ makes cGMP enforcement a top priority. 2013.
http://www.pharmacompliancemonitor.com/the-next-hot-thing-doj-makes-cgmp-enforcement-a-top-priority/5625/
. Accessed 18 June 2014.
5. Clarke T. Europeans, U.S. differ over safety of Ranbaxy facility. 2014.
http://in.reuters.com/article/2014/06/05/ranbaxy-india-idINKBN0EG1PH20140605
. Accessed 5 June 2014.